These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24141829)

  • 1. Attention deficit hyperactivity disorder screening electrocardiograms: a community-based perspective.
    Shahani SA; Evans WN; Mayman GA; Thomas VC
    Pediatr Cardiol; 2014 Mar; 35(3):485-9. PubMed ID: 24141829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of Long-Acting Stimulant and Nonstimulant Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Cerrillo-Urbina AJ; García-Hermoso A; Pardo-Guijarro MJ; Sánchez-López M; Santos-Gómez JL; Martínez-Vizcaíno V
    J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):494-507. PubMed ID: 29897263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder.
    Zhang C; Kutyifa V; Moss AJ; McNitt S; Zareba W; Kaufman ES
    J Cardiovasc Electrophysiol; 2015 Oct; 26(10):1039-44. PubMed ID: 26149510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J; Knecht C; Szerman N; Martinez MI
    CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attention deficit hyperactivity disorder medications in children with heart disease.
    Berger S
    Curr Opin Pediatr; 2016 Oct; 28(5):607-12. PubMed ID: 27261563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
    Faraone SV; Glatt SJ
    J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulant therapy in children with attention-deficit/hyperactivity disorder and concomitant long QT syndrome: A safe combination?
    Rohatgi RK; Bos JM; Ackerman MJ
    Heart Rhythm; 2015 Aug; 12(8):1807-12. PubMed ID: 25956966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder.
    Guevara J; Lozano P; Wickizer T; Mell L; Gephart H
    Pediatrics; 2002 May; 109(5):733-9. PubMed ID: 11986429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication therapy for attention deficit/hyperactivity disorder is associated with lower risk of fracture: a retrospective cohort study.
    Perry BA; Archer KR; Song Y; Ma Y; Green JK; Elefteriou F; Dahir KM
    Osteoporos Int; 2016 Jul; 27(7):2223-2227. PubMed ID: 26928186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulant Medication Treatment in Children with Congenital Heart Disease and Attention-Deficit/Hyperactivity Disorder: Cardiovascular Outcomes.
    Trairatvorakul P; Meinzen-Derr J; Heydarian H; Mason K; Anixt JS
    J Dev Behav Pediatr; 2023 May; 44(4):e247-e254. PubMed ID: 37081695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder.
    Ilgenli TF; Congologlu A; Ozturk C; Turkbay T; Akpinar O; Kilicaslan F
    Adv Ther; 2007; 24(1):182-8. PubMed ID: 17526476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ADHD Treatment in Primary Care: Demographic Factors, Medication Trends, and Treatment Predictors.
    Hauck TS; Lau C; Wing LLF; Kurdyak P; Tu K
    Can J Psychiatry; 2017 Jun; 62(6):393-402. PubMed ID: 28103079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
    Coghill DR; Banaschewski T; Nagy P; Otero IH; Soutullo C; Yan B; Caballero B; Zuddas A
    CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.
    Warren AE; Hamilton RM; Bélanger SA; Gray C; Gow RM; Sanatani S; Côté JM; Lougheed J; LeBlanc J; Martin S; Miles B; Mitchell C; Gorman DA; Weiss M; Schachar R
    Can J Cardiol; 2009 Nov; 25(11):625-30. PubMed ID: 19898693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Debate: Are Stimulant Medications for Attention-Deficit/Hyperactivity Disorder Effective in the Long Term?
    Cortese S
    J Am Acad Child Adolesc Psychiatry; 2019 Oct; 58(10):936. PubMed ID: 31254608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Age, Gender, and Living Circumstances on Patterns of Attention-Deficit/Hyperactivity Disorder Medication Use in Children and Adolescents With or Without Intellectual Disabilities.
    Osunsanmi S; Turk J
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):828-834. PubMed ID: 26982546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic profile and behavioral characteristics during induction of anesthesia in pediatric patients with attention deficit hyperactivity disorder.
    Cartabuke RS; Tobias JD; Rice J; Tumin D
    Paediatr Anaesth; 2017 Apr; 27(4):417-424. PubMed ID: 28181385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.